Nanobiotix S.A. (NBTX) DCF Valuation
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Nanobiotix S.A. (NBTX) Bundle
Streamline your analysis and improve precision with our [NBTX] DCF Calculator! Utilizing real data from Nanobiotix S.A. and customizable assumptions, this tool empowers you to forecast, analyze, and value [Company] like a seasoned investor.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .1 | .1 | .0 | 5.0 | 31.3 | 38.6 | 47.6 | 58.8 | 72.5 | 89.5 |
| Revenue Growth, % | 0 | -26.47 | -80 | 47660 | 529.36 | 23.38 | 23.38 | 23.38 | 23.38 | 23.38 |
| EBITDA | -46.6 | -32.8 | -47.5 | -47.0 | -31.3 | -38.6 | -47.6 | -58.8 | -72.5 | -89.5 |
| EBITDA, % | -65845.59 | -62988 | -456050 | -945.37 | -100.09 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | 1.8 | 1.8 | 1.6 | 1.6 | 1.6 | 26.0 | 32.0 | 39.5 | 48.8 | 60.2 |
| Depreciation, % | 2602.94 | 3510 | 15600 | 31.41 | 5.03 | 67.29 | 67.29 | 67.29 | 67.29 | 67.29 |
| EBIT | -48.4 | -34.6 | -49.1 | -48.6 | -32.9 | -38.6 | -47.6 | -58.8 | -72.5 | -89.5 |
| EBIT, % | -68448.53 | -66498 | -471650 | -976.78 | -105.12 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 36.5 | 124.0 | 87.3 | 43.1 | 78.4 | 38.6 | 47.6 | 58.8 | 72.5 | 89.5 |
| Total Cash, percent | .1 | .2 | .8 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | 4.0 | 7.2 | .1 | 3.1 | 17.6 | 21.7 | 26.8 | 33.1 | 40.8 |
| Account Receivables, % | 16.18 | 7760 | 69260 | 2.11 | 9.87 | 45.63 | 45.63 | 45.63 | 45.63 | 45.63 |
| Inventories | 2.8 | -42.0 | -3.2 | 3.1 | .2 | -2.9 | -3.5 | -4.3 | -5.4 | -6.6 |
| Inventories, % | 3927.94 | -80640 | -30430 | 62.42 | 0.66538 | -7.38 | -7.38 | -7.38 | -7.38 | -7.38 |
| Accounts Payable | 6.4 | 5.8 | 5.2 | 4.2 | 7.0 | 31.3 | 38.7 | 47.7 | 58.9 | 72.6 |
| Accounts Payable, % | 9044.12 | 11148 | 49960 | 83.73 | 22.27 | 81.2 | 81.2 | 81.2 | 81.2 | 81.2 |
| Capital Expenditure | -1.5 | -.1 | -.2 | -.1 | -.4 | -23.4 | -28.9 | -35.6 | -43.9 | -54.2 |
| Capital Expenditure, % | -2123.53 | -214 | -2330 | -1.95 | -1.12 | -60.61 | -60.61 | -60.61 | -60.61 | -60.61 |
| Tax Rate, % | -0.30318 | -0.30318 | -0.30318 | -0.30318 | -0.30318 | -0.30318 | -0.30318 | -0.30318 | -0.30318 | -0.30318 |
| EBITAT | -48.4 | -34.6 | -49.1 | -48.6 | -33.0 | -38.6 | -47.6 | -58.8 | -72.5 | -89.5 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -44.5 | 7.2 | -90.3 | -47.3 | -29.0 | -23.1 | -40.6 | -50.1 | -61.8 | -76.2 |
| WACC, % | 12.59 | 12.59 | 12.59 | 12.59 | 12.59 | 12.59 | 12.59 | 12.59 | 12.59 | 12.59 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -168.2 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -78 | |||||||||
| Terminal Value | -734 | |||||||||
| Present Terminal Value | -406 | |||||||||
| Enterprise Value | -574 | |||||||||
| Net Debt | -26 | |||||||||
| Equity Value | -548 | |||||||||
| Diluted Shares Outstanding, MM | 37 | |||||||||
| Equity Value Per Share | -14.84 |
What You Will Receive
- Pre-Filled Financial Model: Nanobiotix S.A.’s actual data enables accurate DCF valuation.
- Comprehensive Forecast Control: Modify revenue growth, margins, WACC, and other essential drivers.
- Real-Time Calculations: Automatic updates allow you to view results instantly as you make adjustments.
- Professional-Grade Template: A polished Excel file crafted for high-level valuation.
- Customizable and Reusable: Designed for versatility, facilitating repeated use for in-depth forecasts.
Key Features
- Comprehensive NBTX Data: Loaded with Nanobiotix's historical performance metrics and future growth projections.
- Customizable Assumptions: Tailor inputs for revenue growth, profit margins, discount rates, taxation, and capital investments.
- Interactive Valuation Framework: Real-time adjustments to Net Present Value (NPV) and intrinsic value based on user-defined parameters.
- Scenario Analysis: Develop various forecasting scenarios to assess different valuation possibilities.
- Intuitive Interface: Designed for ease of use, catering to both seasoned professionals and newcomers.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered Nanobiotix data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for Nanobiotix’s intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose Nanobiotix S.A. (NBTX)?
- Innovative Solutions: Cutting-edge technology aimed at revolutionizing cancer treatment.
- Proven Expertise: Backed by a team of specialists with extensive experience in nanomedicine.
- Robust Pipeline: A diverse range of product candidates in various stages of development.
- Commitment to Quality: Adherence to the highest standards in research and clinical trials.
- Global Reach: Collaborations with leading institutions and healthcare providers worldwide.
Who Should Use This Product?
- Healthcare Researchers: Explore innovative nanomedicine applications and analyze clinical data.
- Academics: Integrate cutting-edge nanotechnology models into your studies or research projects.
- Investors: Evaluate your investment strategies and assess the potential of Nanobiotix S.A. (NBTX).
- Pharmaceutical Analysts: Enhance your analysis with a customizable model focused on nanotechnology advancements.
- Biotech Entrepreneurs: Understand how leading companies like Nanobiotix S.A. (NBTX) approach market challenges.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Nanobiotix S.A. (NBTX) historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Nanobiotix S.A. (NBTX).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.